AlphAIAlphAI — Financial news for AI agents
investing.comOCT 282 min read$ALGN

Align earnings beat by $0.02, revenue topped estimates

Align (ALGN) reported Q3 EPS of $2.80, beating estimates by $0.02, with revenue at $1.02B, topping consensus. Q4 2026 revenue guidance is $1.00B-$1.02B, below consensus of $1.05B. FY 2026 revenue guidance is $4.11B-$4.13B, below consensus of $4.15B. Stock is down 9.19% in 3 months, up 16.46% in 12 months.

Original reporting
investing.com
Published Oct 28, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ALGN
Bearish
high confidence
Mentioned
$ALGN
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALGNBearishMed
01

Why it matters

The earnings beat may offer short‑term upside, yet the revenue guidance miss is likely to drive the stock lower in the near term.

02

Market read

Earnings and guidance release is a primary catalyst for ALGN, affecting its valuation and potentially influencing peer stocks in the healthcare services sector.

03

What to watch

Potential upcoming contract wins or cost‑control measures not disclosed could mitigate the revenue shortfall.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Align (NASDAQ: ALGN) is a provider of commercial services to the life sciences industry. The company posted Q3 results with a modest earnings beat but guidance below analyst expectations.

Company-level read

Ticker impact

$ALGNBearishHigh confidence
Context

Align reported Q3 EPS beat and revenue beat, but guidance for Q4 and FY 2026 fell short of consensus.

Expected impact

downward pressure as the market prices in the below‑consensus revenue outlook

Evidence & confidence

Guidance miss on revenue is material for a mid‑cap biotech services firm; investors typically react negatively to lower‑than‑expected forward numbers.

Market effects

Sector

May weigh on other healthcare services and biotech outsourcing peers as guidance shortfalls raise concerns about market demand.

Regional

Primarily U.S. market impact; limited regional spillover.

Global

Limited global relevance beyond the healthcare services sector.

Counterpoint

What could challenge this read

The EPS beat could signal operational efficiency; investors might view the guidance miss as temporary and buy on the dip.

Key entities

  • Company
    Align Technology

    Provider of dental and orthodontic services; subject of the earnings report.

Read at source← All news

StoryAlign Technology posts Q3 beat but shares slide on weaker Q4 outlook

Also covered by

3 outlets

Related articles

OCT 28
$ALGNHighAI 8/10

Align Technology stock sheds 5% on weak Q4 revenue outlook

Align Technology (ALGN) reported Q3 2026 earnings beating estimates with $2.80 EPS and $1.02B revenue, but shares fell 5% due to Q4 guidance below expectations. Q4 revenue forecasted at $1.00-$1.02B vs. $1.05B consensus. Full-year revenue expected at $4.11-$4.13B vs. $4.15B estimate. Clear Aligner revenues rose 4.2% YoY, while Imaging Systems revenues declined 7.6% YoY.

investing.com2 min
OCT 28
$ALGNLow

Procter & Gamble's former global healthcare CEO will lead Align on Dec. 31.

Align Technology (ALGN) has appointed Jennifer L. Davis, former CEO of Procter & Gamble’s Global Healthcare, as its new President and CEO effective December 31, 2026. Davis brings 33 years of experience in healthcare and consumer brands. Current CEO Joseph M. Hogan will step down but support the transition. The company also released its third-quarter 2026 financial results and will host a conference call.

stocktitan.net2 min
OCT 28
$ALGNHighAI 8/10

Clear-aligner shipments rose 6.6% to 690,635 cases at Align Technology.

Align Technology reported Q3 2026 revenues of $1.015 billion, up 1.9% YoY. Clear Aligner revenues rose 4.2% YoY to $839.3 million, with shipments up 6.6% to 690,635 cases. Imaging Systems and CAD/CAM Services revenues fell 7.6% YoY. Gross margin was 68.7% (70.4% non-GAAP), and operating margin improved to 16.7% (24.4% non-GAAP). The company repurchased 627.3K shares and expects Q4 revenues between $1.020B and $1.000B.

stocktitan.net3 min